Please login to the form below

Not currently logged in

Merck gets first OK for once-weekly DPP-4 inhibitor

Marizev approved in Japan

Merck & Co has scored its first regulatory approval for omarigliptin, a DPP-4 inhibitor for diabetes that need only be dosed once a week.

Japan's Pharmaceuticals and Medical Devices Agency (PMDA) has approved the drug as Marizev for the treatment of adults with type 2 diabetes, marking the first time that it has been registered in any country around the world.

Marizev cannot claim to be the first weekly DPP-4 inhibitor however; that distinction goes to Takeda, which bagged approval for rival drug Zafatek (trelagliptin succinate) in March.

The new product has been cleared in two doses - 25mg and 12.5mg tablets -on the back of phase III trials that around the world have involved around 8,000 patients and showed that the drug is as effective at controlling blood glucose as daily DPP-4 inhibitors.

That includes Merck's Januvia (sitagliptin), which is heading the DPP-4 inhibitor market with sales of almost $4bn last year.

"More than 6m adults in Japan have type 2 diabetes1 and many still struggle to control their blood sugar levels,” said Tony Alvarez, president of Merck's MSD Japan unit. 

"The approval of Marizev … offers an important option for people in Japan to manage their type 2 diabetes, particularly for those who prefer once-weekly dosing," he added.

The new once-weekly drugs are intended to reduce the burden of taking pills by diabetics and improve compliance. Not all are convinced of the benefit of this approach however, particularly as most patients taking DPP-4 inhibitors also take metformin.

As metformin must be dosed every day, some clinicians argue that it is easier for patients to keep track of dosing the two drugs side by side.

Meanwhile, the diabetes market is becoming increasingly crowded, with the DPP-4 inhibitor class facing a strong challenge from other new drugs such as the SGLT2 inhibitors.

The recently-published data from the EMPA-REG OUTCOME trial of Eli Lilly and Boehringer Ingelheim's leading SGLT2 inhibitor Jardiance (empagliflozin) showing a reduction in all-cause mortality is expected to boost take-up of the latter class, particularly as Januvia failed to show such a benefit in the TECOS trial.

Article by
Phil Taylor

29th September 2015

From: Regulatory



Featured jobs

Subscribe to our email news alerts


Add my company
Create Health

A healthcare marketing agency that shares your passion for making things better. Our clients with solve real health problems every...

Latest intelligence

Waking the sleeping giant
The lights are coming on for healthcare delivery in Africa...
How to get rep buy-in for multi-channel
How do you manage a team who may be resistant to change?...
Blog: Digital therapeutics: within our reach?
Digital therapeutics is a hot topic right now. By using digital technology to manage, treat or even prevent chronic conditions, digital therapeutics is promising to revolutionise healthcare. But is this...